NKTR Earnings Prediction
The chart below shows how NKTR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NKTR sees a +1.09% change in stock price 10 days leading up to the earnings, and a -14.35% change 10 days following the report. On the earnings day itself, the stock moves by +0.86%. This data can give you a slight idea of what to expect for the next quarter's release.
NKTR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
24.12M
-0.08%
2.70%
Gross Margin
81.62%
68.25%
39.45%
Operating Margin
-142.18%
2.46%
-8.47%
Net Margin
-153.61%
-19.09%
-31.09%
EPS
-0.18
-25.00%
-28.00%
No Data Available
NKTR Earnings Analysis
Nektar Therapeutics Corporation (NKTR.O) Earnings Conference Call
Positive
Pipeline Advancement in Immunology: During the third quarter, we made significant progress in advancing our highly promising pipeline, focused on immunology and inflammation.
Immunotherapy for Autoimmune Disorders: Our lead asset, rezpegaldelesleukin, is designed to directly expand functional Treg cells and engage multiple immunoregulatory pathways in patients with autoimmune disorders.
Phase 2 Study Enrollment: Enrollment in our Phase 2 study in ectopic dermatosis is on track with a top lined data readout in the first half of 2025.
Strong Cash Position: We ended the third quarter with $249 million in cash and investments and with no debt on our balance sheet.
Projected Cash and Investments: We expect to end 2024 with approximately $265 million in cash and investments.
Negative
Revenue Below Expectations: Our revenue was $24.1 million for the third quarter of 2024, which is below expectations.
Revenue Forecast Decline: We expect our revenue for the full year to be between $90 million and $95 million, which includes $30 million to $35 million in product sales, indicating a decline from previous forecasts.
Negative Gross Margin Concerns: Our product sales generate a negative gross margin, which is concerning for our financial health.
R&D Expense Increase: R&D expense for the third quarter of 2024 was $35 million, indicating a significant increase in costs without corresponding revenue growth.
Quarterly Net Loss: Our net loss for the third quarter of 2024 was $37 million, or $0.18 basic and diluted loss per share, reflecting ongoing financial challenges.
NKTR FAQs
How does NKTR typically perform around its earnings report dates?
Is Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NKTR Earning Call Sentiment
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
NKTR.O
5.5%Positive
The earnings call presents a mixed picture. While the sale of the manufacturing facility and cash runway extension are positives, competitive pressures and clinical development risks are concerns. The Q&A session highlights uncertainties, particularly around litigation and clinical outcomes. Revenue guidance shows modest growth, but net losses persist. Overall, the sentiment remains neutral, balancing positive financial moves with significant risks and uncertainties.
